172 related articles for article (PubMed ID: 35026706)
1. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
[TBL] [Abstract][Full Text] [Related]
2. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer and prostate-specific antigen testing in New South Wales.
Smith DP; Supramaniam R; Marshall VR; Armstrong BK
Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
[TBL] [Abstract][Full Text] [Related]
4. Changes in prostate specific antigen (PSA) "screening" patterns by geographic region and socio-economic status in Australia: Analysis of medicare data in 50-69 year old men.
Kohar A; Cramb SM; Pickles K; Smith DP; Baade PD
Cancer Epidemiol; 2023 Apr; 83():102338. PubMed ID: 36841020
[TBL] [Abstract][Full Text] [Related]
5. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
6. Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia.
Luo Q; Yu XQ; Kahn C; Egger S; Patel MI; Grogan PB; Caruana M; Canfell K; Smith DP; O'Connell DL
Cancer Epidemiol; 2022 Jun; 78():102159. PubMed ID: 35447540
[TBL] [Abstract][Full Text] [Related]
7. Benefits and harms of prostate specific antigen testing according to Australian guidelines.
Caruana M; Gulati R; Etzioni R; Barratt A; Armstrong BK; Chiam K; Nair-Shalliker V; Luo Q; Bang A; Grogan P; Smith DP; O'Connell DL; Canfell K
Int J Cancer; 2024 Feb; 154(4):648-658. PubMed ID: 37819139
[TBL] [Abstract][Full Text] [Related]
8. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
10. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia.
Coory MD; Baade PD
Med J Aust; 2005 Feb; 182(3):112-5. PubMed ID: 15698354
[TBL] [Abstract][Full Text] [Related]
11. Rising incidence of prostate cancer in Scotland: increased risk or increased detection?
Brewster DH; Fraser LA; Harris V; Black RJ
BJU Int; 2000 Mar; 85(4):463-72; discussion 472-3. PubMed ID: 10691826
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996.
Threlfall TJ; English DR; Rouse IL
Med J Aust; 1998 Jul; 169(1):21-4. PubMed ID: 9695697
[TBL] [Abstract][Full Text] [Related]
13. Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
Albertsen PC; Bjerner LJ; Pasovic L; Müller S; Fosså S; Carlsson SV; Oldenburg J
BJU Int; 2024 Jan; 133(1):104-111. PubMed ID: 37869764
[TBL] [Abstract][Full Text] [Related]
14. Recent trends in prostate cancer incidence and mortality in southeast England.
Evans HS; Møller H
Eur Urol; 2003 Apr; 43(4):337-41. PubMed ID: 12667713
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
16. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
17. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
Varghese J; Kuruvilla PM; Mehta N; Rathore RS; Babu M; Bansal D; Pillai B; Sam MP; Krishnamorthy H
Asian Pac J Cancer Prev; 2016; 17(4):2255-8. PubMed ID: 27221926
[TBL] [Abstract][Full Text] [Related]
18. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
Jones JS; Follis HW; Johnson JR
Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer--testing, incidence, surgery and mortality.
Gibbons L; Waters C
Health Rep; 2003 May; 14(3):9-20. PubMed ID: 12816012
[TBL] [Abstract][Full Text] [Related]
20. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]